Sederma SAS launched a skin brightening ingredient with a new mechanism of action from the heart of the melanocyte. O.D.A.white (INCI Not Provided) was designed to treat skin pigmentation disorders such as freckles, melasma, hyperpigmentation and general dark color of ethnic skin.
The enzyme tyrosinase is the target for this interference, as it is the limiting factor of the rate of melanogenesis. While many skin lightening ingredients inhibit tyrosinase, O.D.A.white reportedly decreases melanin synthesis via another, further upstream mechanism.
The skin lightening ingredient does not mediate melanin synthesis reduction by a direct inhibition of tyrosinase, but can inhibit the whole melanin synthesis pathway from the melanocyte nucleus by targeting the tyrosinase gene via the PPARg complex. Testing conducted by the company showed a 50% decrease in mRNA tyrosinase and tyrosinase quantities, a decrease of the pigmentation by 44 and a 28% increase in skin clarity. According to the company, the ingredient also brightens the skin. For more information, visit www.sederma.fr.
